Osteonecrosis maxilar por denosumaba propósito de un caso

Laburpena

Osteonecrosis of the jaw (ONJ) induced by antiresorptive drugs, mainly bisphosphonates (BF), is widely described in the scientific literature. In recent years, there have been reports of ONJ induced by other antiresorptive drugs such as Denosumab, Bevacizumab and Sunitinib used in cancer patients. Denosumab is a monoclonal antibody that is used in the treatment of osteoporosis and in the prevention of fractures following the treatment of some types of cancer. In this article, we present the case of a patient who developed ONJ. The patient had periodontal disease and osteoporosis, which had been treated for years with Alendronate (oral bisphosphonate) and currently with Denosumab. In addition, she had a poorly adapted removable prosthesis. This work discusses the risk of ONJ associated with these drugs, and the possible influence on their occurrence of certain factors at the local level, as well as the preventive and therapeutic measures that should be adopted in these cases.